Hawthorn

Hawthorn Therapeutics is a clinical-stage biotechnology company and a subsidiary of BridgeBio Pharma, dedicated to developing targeted therapies for rare genetic diseases. The company's primary focus is the development of BBP-681, a topical formulation of the PI3K alpha inhibitor alpelisib, for the treatment of venous malformations and other PIK3CA-related overgrowth spectrum (PROS) disorders. By delivering the medication topically, Hawthorn aims to provide a localized treatment that minimizes systemic side effects while addressing the underlying genetic drivers of vascular lesions. As a spoke within the BridgeBio ecosystem, the company leverages centralized resources to advance its specific pipeline of targeted therapies for high-unmet-need indications.